TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-26

Study Completion Date

2024-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

NCT06961786

Metastatic Melanoma

RECRUITING PHASE1

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

NCT04924413

Malignant Melanoma

TERMINATED PHASE2

Vemurafenib and TIL Therapy for Metastatic Melanoma

NCT02354690

Metastatic Melanoma

COMPLETED PHASE1/PHASE2

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

NCT06961357

Melanoma

RECRUITING PHASE1/PHASE2

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470

Metastatic Uveal Melanoma Metastatic Cutaneous Melanoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the trial is to evaluate the safety of TILT-123. The approach has the potential to a) increase the efficacy of adoptive T-cell therapy, b) remove the need for toxic pre- and post-conditioning regimens, c) yield the combined anti-tumor benefits of armed oncolytic viruses and T-cell therapy.

Dose escalation of TILT-123 injection will take place between cohorts not intra-patient and will be determined based on Dose Limiting Toxicities (DLTs).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

open-label, single arm, dose escalation

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TILT-123

Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.

Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level.

Group Type EXPERIMENTAL

TILT-123

Intervention Type BIOLOGICAL

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated informed consent before any trial-related activities.
* Male or female, between 18-75 years of age (both included).
* Pathologically confirmed previously treated refractory or recurrent stage 3-4 melanoma, which cannot be treated with curative intent with available therapies.
* At least one prior line of medical treatment is required (for example checkpoint inhibitors, kinase inhibitors, interleukin-2). Multiple prior therapies (e.g. surgery, checkpoint inhibitors, kinase inhibitors, interleukin-2, interferon, chemotherapy, radiation) are allowed.
* A \> 9 mm tumor (in diameter, typically a minimum of 1 cm3 in volume) without signs of necrosis must be available for biopsy/operation to enable growing of TILs.
* At least one additional tumor (\>14 mm in diameter) must be available for injections and biopsies for correlative analyses. The disease burden must be measurable, but does not need to fulfil RECIST 1.1.
* Eligible for adoptive T-cell therapy with tumor infiltrating lymphocytes

Adequate hepatic, cardiac and renal functions as following:

1. Platelets \> 75 000/mm3
2. Haemoglobin ≥ 100 g/L.
3. AST and ALT \< 3 x ULN.
4. GFR \>60 ml/min (Cockcroft-Gault formula).
5. Leukocytes (WBC) \> 3,0
6. Bilirubin \<1.5 x ULN

* Men and women must be willing to use adequate forms of contraception from screening, during the trial, and for a minimum of 90 days after end of treatment, in accordance with the following:
* Women of childbearing potential: Barrier contraceptive method (i.e. condom) must be used in addition to one of the following methods: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections).
* Women not of childbearing potential: Barrier contraceptive method (i.e. condom) must be used.
* Men: Barrier contraceptive method (i.e. condom) must be used.
* Demonstrated WHO performance score of 0-1 at screening.
* Life expectancy time longer than 3 months.
* Capable of understanding and complying with parameters as outlined in the protocol.
* BRAF negative or positive.

Exclusion Criteria

* Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy; pulmonal and topical treatments; up to 20 mg of prednisone/prednisolone.
* History of another active invasive cancer as judged by the investigator within the past 3 years except basalioma.
* Treated with any anti-cancer therapy for melanoma 30 days prior to enrolment. Anti-cancer therapy for melanoma is defined as anti-cancer agents (immunotherapy, signal-transduction inhibitors \[e.g. BRAF and MEK inhibitors\], cytotoxic chemotherapy), radiotherapy and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans.
* Uncontrolled cardiac or vascular diseases.
* History of heart attack or cerebral stroke within the previous 12 months before screening or is not recovered from an older heart attack or cerebral stroke.
* LDH value \> 3 x ULN.
* History of hepatic dysfunction, hepatitis or HIV.
* History of coagulation disorder.
* Any other disease which prevent participation in the opinion of the investigator.
* Female patients who are pregnant, breastfeeding or intends to become pregnant.
* Untreated brain metastases. Treated brain metastases which have not progressed in 3 months prior to screening are allowed.
* Previously treated with any oncolytic adenovirus that was administered intratumorally.
* Previously treated with adoptive cell therapy.
* Allergy to TILT-123, TIL, or ingredients present in the investigational medicinal products.
* Administered an investigational medicinal product or device in another clinical trial within 30 days prior to screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No